Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition. Celltrion and Teva's ...
Reviews of apixaban in active cancer, Medicare costs after CAR T-cell therapy, and the need for financial assistance for novel therapies. Patients with cancer who took apixaban to prevent blood clots ...
(WASHINGTON, November 7, 2019) - The American Society of Hematology (ASH) is pleased to recognize the following trainees, whose meritorious scientific abstract has received one of the awards in the ...
ORLANDO, Fla. – Data from two studies from Forty Seven Inc. announced at the American Society of Hematology (ASH) annual meeting is moving the market in a major way as the company stock (NASDAQ: FTSV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results